Predicting PML in natalizumab-treated patients: can we do better?

被引：3
作者：
Derfuss, Tobias [1 ,2 ]
Kappos, Ludwig [1 ,2 ]
机构：
[1] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland
[2] Univ Basel, Dept Biomed, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2013年 / 84卷 / 11期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSING MULTIPLE-SCLEROSIS; JC VIRUS;
D O I：
10.1136/jnnp-2012-304777
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1182 / 1183
页数：2
相关论文
共 13 条
  • [11] Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
    Trampe, A. K.
    Hemmelmann, C.
    Stroet, A.
    Haghikia, A.
    Hellwig, K.
    Wiendl, H.
    Goelz, S.
    Ziegler, A.
    Gold, R.
    Chan, A.
    [J]. NEUROLOGY, 2012, 78 (22) : 1736 - 1742
  • [12] Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
    Vermersch, P.
    Kappos, L.
    Gold, R.
    Foley, J. F.
    Olsson, T.
    Cadavid, D.
    Bozic, C.
    Richman, S.
    [J]. NEUROLOGY, 2011, 76 (20) : 1697 - 1704
  • [13] Changes to anti-JCV antibody levels in a Swedish national MS cohort
    Warnke, Clemens
    Ramanujam, Ryan
    Plavina, Tatiana
    Bergstrom, Tomas
    Goelz, Susan
    Subramanyam, Meena
    Kockum, Ingrid
    Rahbar, Afsar
    Kieseier, Bernd C.
    Holmen, Carolina
    Olsson, Tomas
    Hillert, Jan
    Fogdell-Hahn, Anna
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (11) : 1199 - 1205
12